Stage III Rectal Cancer: Clinical Trials

3 trials for Stage III Rectal Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 completed. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Terminated 2, Completed 1

Follow Stage III Rectal Cancer: new trials by email Literature Review of Stage III Rectal Cancer trials Research Report on Stage III Rectal Cancer

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
oxaliplatin, fluorouracil, leucovorin calcium - Adenocarcinoma of the Rectum, Stage II Rectal Cancer
Phase 3TerminatedECOG-ACRIN Cancer Research Group3552006-05-112023-07-06
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
oxaliplatin, leucovorin calcium, capecitabine - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Phase 3TerminatedNational Cancer Institute (NCI)22002004-04-012013-01-25
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
bevacizumab, oxaliplatin, leucovorin calcium - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Phase 3CompletedNational Cancer Institute (NCI)8802001-09-012013-01-24

Narrower conditions

Rectal Neoplasms (3)  ·  Colonic Neoplasms (2)

Broader conditions

Colorectal Neoplasms (3)  ·  Digestive System Diseases (3)  ·  Digestive System Neoplasms (3)  ·  Gastrointestinal Diseases (3)  ·  Gastrointestinal Neoplasms (3)  ·  Intestinal Diseases (3)  ·  Intestinal Neoplasms (3)  ·  Neoplasms (3)  ·  Neoplasms by Site (3)  ·  Rectal Diseases (3)  ·  Colonic Diseases (2)

Interventions

Bevacizumab (3)  ·  Fluorouracil (3)  ·  Leucovorin (3)  ·  Oxaliplatin (3)  ·  Capecitabine (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  ECOG-ACRIN Cancer Research Group (1)

Countries

United States (3)  ·  Canada (1)  ·  Peru (1)  ·  Puerto Rico (1)

Top investigators

Al Benson (1)  ·  Bruce Giantonio (1)  ·  Charles Blanke (1)

NIH funding

U10CA021115 (2), U10CA032102 (1)